ReWalk Robotics inks $20m private placement, posts Q4, 2017 earnings

March 8, 2018 By Fink Densford Leave a Comment

Shares in ReWalk Robotics (NSDQ:RWLK) have risen today after the company announced a $20 million private placement and posted shrinking losses for the quarter and growing sales for the year with its fourth quarter and 2017 earnings.

The company said it inked an investment agreement with Hong Kong-based Timwell Corporation Limited through which the company will receive $20 million in three tranches through the issuance of 16 million shares at a price of $1.25 per share.

The investment will come in three tranches, with $5 million for an initial 4 million shares in the first, $10 million for 8 million shares in the second and an additional $5 million for 4 million shares in the third.

Upon closure of the third tranche, Timwell will own approximately 34.8% of the company’s shares, ReWalk said in an SEC filing.

The Israel-based company posted losses of $6.2 million, or 25¢ per share, on sales of $1.5 million for the 3 months ended December 31, seeing losses shrink by 27.9% while sales shrunk 4.8% when compared to the same period during the previous year.

Losses per share were ahead of the 26¢ consensus on Wall Street where analysts expected to see sales of $2 million.

For the full year, ReWalk Robotics posted losses of $24.7 million, or $1.22 per share, on sales of $7.8 million, seeing losses shrink 24% while sales grew 32.1% compared with the previous fiscal year.

Losses per share were just behind the $1.08 consensus on Wall Street, where analysts were expecting to see sales of $8.2 million.

“2017 was an important year as we achieved record revenue of $7.8 million and positioned ourselves for additional growth in 2018. We secured broader reimbursement in Germany, facilitating access to the ReWalk system for millions of people and providing qualified individuals with the coverage they need. In the U.S., we are focusing our reimbursement efforts on 25 national and regional providers and have recently submitted coverage proposals to three additional commercial groups. In 2018, our key priorities are securing broader U.S. reimbursement, executing on our joint venture with Timwell to bring our products to market in China, advancing the Restore for stroke patients through clinical studies with a targeted launch in the first half of 2019, and strengthening our capital structure to execute our strategic plan,” CEO Larry Jasinski said in a press release.

The company released guidance for 2018, expecting to see sales between $9 million and $11 million through sales of its SCI exoskeletons, with any sales of Restore, if cleared, being additive to those numbers.

Shares in ReWalk Robotics were up 6.8% at $1.17 as of 3:59 p.m. EST.

Inside Hologic's evolving definition of women's healthcare

Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.

At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!

REGISTER NOW

Use code WOMENSHEALTH to save an additional 10%.

Medtech should think deeper about the problems its trying to solve
Medtech can improve by thinking more about the problems it is trying to solve and looking outside of normal avenues for inspiration. Jeff Karp, Brigham and Women’s Hospital, Harvard Medical School. For companies and academics aiming to innovate in the medical space, we often don’t spend enough time thinking about the problem we are trying… […]
5 tips for post-market medical device compliance
Post-market surveillance is an important process for medical device developers and an expectation of regulatory bodies that you follow through and have effective procedures. Jon Speer, Greenlight Guru In fact, post-market surveillance is a compliance issue that many companies get caught up with in audits or inspections. So how comfortable is your medtech company with the… […]
11 pediatric cardiovascular devices you need to know
A bandage-sized heart monitor, an extracorporeal blood pump that mimics the human heart, and a heart valve that can grow with a child were among the six winners of a contest yesterday in Philadelphia for innovative pediatric cardiovascular devices. The Pediatric Device Innovation Symposium organized by the Sheikh Zayed Institute for Pediatric Surgical Innovation at… […]
Meddux Development receives ISO 13485:2016 certification
Meddux Development announced that it has received ISO 13485:2016 certification for its quality management system. “The certification to ISO 13485:2016 allows Meddux to offer its customers a streamlined path from concept to first-in-human clinical trials, David Schechter, president of Meddux, said. “Meddux has developed a flexible and responsive QMS capable of handling the most critical… […]
6 questions to ask when designing polymer components for medical devices
Choosing the right polymer for the job can be a daunting task. Here are the right questions to ask before you begin the process. Karen Heroldt, PolyOne Distribution Choosing polymers is complicated in the high-stakes world of medical and healthcare devices. Materials can have varied tool design, molding and secondary processing requirements that can affect… […]
Medtech M&A remains hot: Here’s how
M&A in medtech show no signs of slowing in the fourth quarter of 2018, and companies looking to buy or sell have much to consider, according to patent attorney David Dykeman, a shareholder in the Boston office of the global law firm Greenberg Traurig. The number of medtech M&A deals soared by 50% in 2017 and… […]
Olympus touts line of needles for GI disease improvement
Olympus is touting its new EZ Shot 3 Plus 25 G needles that is designed to help improve the staging of GI disease. The 25 G needle is an addition to the EZ Shot 3 Plus 19 G and 22 G needles that Olympus already markets. Olympus’s new EZ Shot 3 Plus 25 G needles… […]
Mindray North America picks Eastman medical polymers for patient monitors
Mindray is using Eastman’s medical polymers in its present generation of patient monitors in order to improve chemical resistance to cleaning/disinfection agents and increase device longevity, the companies recently announced. Thanks to the Eastman polymers, Mindray’s Passport series of bedside monitors, T1 monitor/module and Accutorr series of spot check monitors are now fully compatible with more than… […]
Cincinnati Children’s researchers report progress growing a human esophagus in a lab
It’s possible to use pluripotent stem cells to grow human esophageal organoids — another step toward the goal of someday bioengineering the entire esophagus and human gastrointestinal system in a lab, according to researchers at Cincinnati Children’s Center for Stem Cell and Organoid Medicine (CuSTOM). The Cincinnati Children’s researchers describe the advance as a first. Pluripotent stem… […]
How strong patent portfolios attract strategic investments and deals
Amassing strong patent portfolios helps medical device companies attract interest from strategic investors and potential acquirers. David J. Dykeman, Greenberg Traurig and Patrick West, Mirus Capital Advisors The medical device industry has demonstrated strong and sustainable growth in recent years. Given the aging population, increasing incidence of chronic and lifestyle diseases, emergence of artificial intelligence (AI)… […]
NucleusHealth wins investment from large Ohio health system
Cloud-based medical image exchange company NucleusHealth has landed an undisclosed “strategic investment” from Mercy Health, an Ohio–based health care system that is now a minority investor in the San Diego, Calif.-based company. NucleusHealth will use the money to help deliver Nucleus.io, the first cloud-based Picture Archiving Communications System (PACS) platform designed to use the security, scalability and… […]